menu search

Reviva pharmaceuticals: positive results in phase 3 but the stock is back where it started

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia...

November 2, 2023, 3:11 am

Reviva pharma's schizophrenia drug succeeds in late-stage study

Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia...

October 30, 2023, 7:41 am

Karuna therapeutics: karxt could become a new standard of care in schizophrenia

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating ...

October 16, 2023, 2:41 pm

Karuna therapeutics to present data from the emergent program evaluating karxt in schizophrenia at the 36th european college of neuropsychopharmacology (ecnp) congress

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative...

October 4, 2023, 6:30 am

Karuna (krtx) submits nda filing to fda for schizophrenia drug

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in ...

September 29, 2023, 2:17 pm

Why shares of bioxcel therapeutics fell this week

The company has one marketed treatment -- Igalmi, which reduces agitation in patients with bipolar disorder or ...

September 28, 2023, 5:35 pm

Reviva pharmaceuticals: a binary event approaches with results from recover

Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, wit...

September 27, 2023, 2:48 am

Atai life sciences: rl-007, targeting schizophrenia subpopulation with no fda approved therapies

Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia...

September 1, 2023, 7:02 pm

Karuna: nda filing q3 of 2023 and expanded potential with karxt

Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023....

August 24, 2023, 2:54 pm

Minerva neurosciences: there's probably time for one more rally

Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private plac...

August 23, 2023, 4:05 am

Karuna's robust liquidity paves way for karxt milestones (rating upgrade)

Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting ...

August 16, 2023, 5:08 pm

Reviva pharmaceuticals announces 80% global enrollment update for pivotal phase 3 recover study evaluating brilaroxazine for schizophrenia

– Enrollment ongoing at multiple sites in the US, Europe, and Asia – – Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supp...

June 22, 2023, 10:00 am

Golden schizophrenia

Source: Michael Ballanger (6/12/23) Michael Ballanger of GGM Advisory Inc. shares his opinion on the current state of the gold market as the U.S. fede...

June 14, 2023, 1:13 pm

Intra-cellular therapies: depression data boosts investment prospects (rating upgrade)

Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond ...

May 25, 2023, 7:51 pm

Why shares of bioxcel therapeutics are dropping thursday

BioXcel Therapeutics got approval last year for Igalmi to treat acute agitation in adults with schizophrenia...

May 25, 2023, 12:40 pm

Bioxcel stock crashes 22% as bid to double its market appears less certain

Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizo...

May 25, 2023, 12:04 pm

schizophrenia drugs market size to witness healthy valuation of us$ 12.6 billion at 5.6% cagr by 2032 | market.us report

A higher prevalence of schizophrenia has directly influenced the growth trajectory of the ...

May 25, 2023, 11:54 am

Antipsychotic drugs market size to hit usd 33.5 billion by 2030 at 5.70% cagr – report by market research future (mrfr)

Antipsychotic Drugs Market Trends and Insights By Generation (First Generation, Second Generation), By Type (Atypical Antipsychotic, Miscellaneous Ant...

May 23, 2023, 5:30 pm

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am


Search within

Pages Search Results: